- ‘Moneybags’ Tesaro prices $85m public offering
- $65m Series D supports Pearl's twice-daily COPD combo but more funds needed
- IPO hope for post-Novartis antibiotic developer Paratek
- Stockwatch: Yard sale drug development
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.